urease/vomiting

the study included 400 patients recruited from Gastroenterology as well as general internal medicine clinic at Internal Medicine department, Faculty of Medicine, University of Alexandria, Egypt. After initial evaluation, every participant was randomly assigned to one of four equal treatment regimens

This study aims to evaluate: 1. the first line H. pylori eradication rate of high dose dual therapy with 14 days rabeprazole 20 mg qid, plus amoxicillin 500 mg qid (HDDT group) comparing to the clarithromycin-based triple therapy with 14 days clarithromycin 500 mg bid, amoxicillin 1000mg bid , and

Introduction: H. pylori has been declared and ratified as carcinogen I by the World health organization (WHO) International agency for research on cancer (IARC). Globally first line therapy eradication treatment recommended for H. pylori, combines a proton-pump inhibitor (PPI) with two antibiotics

The aim of our prospective study is to investigate the rate of H pylori resistant strains to antibiotic treatment including Amoxicillin, Clarithromycin, Metronidazole, Tetracycline and Quinolones in pediatric population in Ha-Emek medical center, Afula. The second aim was to determine if in vitro

From 1st February 2006 till 31st December 2008, 800 cases of diabetes mellitus who attended the diabetes clinic constituted the subjects for the present study. Majority of the subjects were from the state of Uttar Pradesh (UP). UP is the fifth largest state of India, Lucknow being the capital of UP.

Determination of H. pylori status Prior to enrollment, the status of H. pylori infection will be determined by (1) rapid urease test (CLO test, Kimberly-Clark, USA) from antrum biopsy, (2) histological examination (Giemsa stain) of antral and body samples (two from the antral mucosa and two from the